Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd⁺²or As⁺³transformed human urothelial cells

• Main Authors: Ajjimaporn Amornpan, Zheng Yun, Zhou Xu, Toni Conrad, Garrett Scott H, Somji Seema, Sens Mary, Sens Donald A
• Format: Article
• Language: English
• Published: BMC 2011-02-01
• Series: Cancer Cell International
• Online Access: http://www.cancerci.com/content/11/1/2

<p>Abstract</p> <p>Background</p> <p>Studies have shown that metallothionein 3 (MT-3) is not expressed in normal urothelium or in the UROtsa cell line, but is expressed in urothelial cancer and in tumors generated from the UROtsa cells that have been transformed by cadmium (Cd⁺²) or arsenite (As⁺³).The present study had two major goals. One, to determine if epigenetic modifications control urothelial MT-3 gene expression and if regulation is altered by malignant transformation by Cd⁺²or As⁺³. Two, to determine if MT-3 expression might translate clinically as a biomarker for malignant urothelial cells released into the urine.</p> <p>Results</p> <p>The histone deacetylase inhibitor MS-275 induced MT-3 mRNA expression in both parental UROtsa cells and their transformed counterparts. The demethylating agent, 5-Aza-2'-deoxycytidine (5-AZC) had no effect on MT-3 mRNA expression. ChIP analysis showed that metal-responsive transformation factor-1 (MTF-1) binding to metal response elements (MRE) elements of the MT-3 promoter was restricted in parental UROtsa cells, but MTF-1 binding to the MREs was unrestricted in the transformed cell lines. Histone modifications at acetyl H4, trimethyl H3K4, trimethyl H3K27, and trimethyl H3K9 were compared between the parental and transformed cell lines in the presence and absence of MS-275. The pattern of histone modifications suggested that the MT-3 promoter in the Cd⁺²and As⁺³transformed cells has gained bivalent chromatin structure, having elements of being "transcriptionally repressed" and "transcription ready", when compared to parental cells. An analysis of MT-3 staining in urinary cytologies showed that a subset of both active and non-active patients with urothelial cancer shed positive cells in their urine, but that control patients only rarely shed MT-3 positive cells.</p> <p>Conclusion</p> <p>The MT-3 gene is silenced in non-transformed urothelial cells by a mechanism involving histone modification of the MT-3 promoter. In contrast, transformation of the urothelial cells with either Cd⁺²or As⁺³modified the chromatin of the MT-3 promoter to a bivalent state of promoter readiness. Urinary cytology for MT-3 positive cells would not improve the diagnosis of urothelial cancer, but might have potential as a biomarker for tumor progression.</p>